3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
2
Thoracic
1
Sarcoma
1
Gastrointestinal
1
Conditions
Colorectal Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Thyroid Cancer, Papillary
1
Squamous Cell Carcinoma of Head and Neck
1
Solitary Fibrous Tumors
1
Sarcoma
1
Neoplasms
1
Mesothelioma
1
Melanoma
1
Liposarcoma
1
Histiocytoma, Malignant Fibrous
1
Dermatofibrosarcoma
1
Interventions
pembrolizumab
70
Nivolumab
24
Docetaxel
17
Cisplatin
15
Paclitaxel
13
Carboplatin
12
Gemcitabine
8
Cetuximab
8
Ipilimumab
7
durvalumab
6
avelumab
6
atezolizumab
6
Radiotherapy
6
Cyclophosphamide
6
spartalizumab
5
Trastuzumab
5
Taxes
5
Pemetrexed
5
Erlotinib Hydrochloride
5
tremelimumab
4
cemiplimab
4
Specimen Handling
4
Leucovorin
4
Interleukin-2
4
Fluorouracil
4
Capecitabine
4
Biopsy
4
Albumin-Bound Paclitaxel
4
130-nm albumin-bound paclitaxel
4
utomilumab
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Squamous Cell Carcinoma of Head and Neck
×
Famotidine
×
Thoracic
×
Clear all
NCT06789172
2026-05-22
INVOKE
Epkin
Phase 1
Recruiting
166 enrolled